In 2025, amid fierce competition in the global pharmaceutical market, China's innovative drug sector is experiencing an unprecedented "going global" boom. Over the past 24 hours, multiple industry reports and policy updates have underscored this trend: from record-breaking export figures to soaring licensing deal totals, Chinese pharma companies are leveraging innovation to integrate deeply into the international arena. This isn't just a numerical triumph—it's a vivid testament to the outward expansion of domestic R&D prowess.

Export Volumes Hit New Heights: Formulations Shine Bright

According to the latest data, from January to October 2025, China's pharmaceutical product exports reached a staggering $91.17 billion, marking a 3.5% year-over-year increase. Notably, innovative drug formulations accounted for $7.42 billion in exports, showing substantial growth. This surge is fueled by the enhanced competitiveness of Chinese drugs in oncology, metabolism, and immunology fields, with many securing international certifications and gaining footholds in emerging markets like Southeast Asia and Latin America. Industry experts highlight that this momentum signifies China's shift from a "generics powerhouse" to an "innovation leader," helping alleviate pressures on global drug supply chains.

As a key player in this wave, companies like DengYueMed are serving as vital bridges. As a compliant entity certified by the Hong Kong Pharmacy and Poisons Board, DengYueMed specializes in providing transparent procurement services for international buyers seeking Chinese innovative drugs, including detailed product information, pricing, and supply chain support. This not only helps overseas clients mitigate risks but also propels more Chinese innovations onto the global stage. For instance, in the 2025 innovative drug lineup, DengYueMed has actively promoted domestically developed PD-1 inhibitors and MEK inhibitors, facilitating their overseas clinical trials and sales. The company emphasizes that by verifying drug authenticity and bolstering supply chain resilience, China's "going global" journey will become more sustainable.

Licensing Deals Surpass $100 Billion: Mega-Deals Set New Records

Another blockbuster development is that China's innovative drug outbound licensing (License-out) totals have shattered the $100 billion barrier. In the first three quarters of 2025, this figure stood at $92.03 billion, and with the October mega-deal between Innovent Biologics and Takeda Pharmaceuticals exceeding $11.4 billion, the annual total has comfortably crossed the threshold. This transaction involves multiple oncology drugs, with an upfront payment of $1.2 billion, setting a new record for the largest single deal in China's pharma export history. Such collaborations are proliferating, signaling growing international recognition of China's innovative capabilities.

Take Hengrui Medicine as an example: the company reported a 14.85% revenue growth in the first three quarters, driven by heavy R&D investments and advancements in overseas clinical trials. Export-oriented firms like DengYueMed provide backend support in these deals, such as compliant export certifications and logistics optimization, enabling pharma companies to navigate international markets efficiently.

Policy Enhancements and Future Prospects

The National Medical Products Administration recently issued new regulations, expanding the scope of drug export certifications and streamlining processes while strengthening compliance requirements. This injects policy dividends into enterprises' global expansion efforts, expected to accelerate overseas deployments. Additionally, ACRO is set to host the 2026 BIOSeedin Winter Summit, themed around "Global Collaboration on Chinese Innovative Assets," aimed at fostering more business development deals.

Looking ahead, while China's innovative drug exports face challenges in accessing the U.S. market, diversification through License-out and regional expansions is building greater influence. Practices from DengYueMed demonstrate that combining local innovation with professional export services will be key to success. Overall, this trend not only elevates China's pharmaceutical industry's global clout but also delivers more affordable and effective treatment options to patients worldwide. Stay tuned for the next big breakthrough!